Amgen (AMGN) Accumulated Expenses (2009 - 2026)

Amgen (AMGN) has reported Accumulated Expenses for 18 consecutive years, with $16.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 3.78% year-over-year to $16.6 billion; the TTM figure through Mar 2026 stood at $16.6 billion (down 3.78% YoY), while the FY2025 annual figure was $18.5 billion, up 5.0% from the prior year.
• Accumulated Expenses came in at $16.6 billion for Q1 2026 at Amgen, down from $18.5 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $18.5 billion in Q4 2025, with the low at $10.5 billion in Q2 2022.
• Average Accumulated Expenses over 5 years is $14.4 billion, with a median of $14.2 billion recorded in 2023.
• Across the five-year window, Accumulated Expenses surged 30.09% in 2023 and retreated 3.78% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $12.5 billion in 2022, then gained by 22.64% to $15.4 billion in 2023, then grew by 14.86% to $17.6 billion in 2024, then grew by 5.0% to $18.5 billion in 2025, then dropped by 10.47% to $16.6 billion in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $16.6 billion, $18.5 billion, and $16.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.